NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 24 04:00PM ET
14.97
Dollar change
+0.40
Percentage change
2.75
%
Index- P/E- EPS (ttm)-1.58 Insider Own6.46% Shs Outstand25.55M Perf Week-4.95%
Market Cap392.96M Forward P/E- EPS next Y-1.55 Insider Trans131.74% Shs Float24.55M Perf Month10.15%
Enterprise Value290.27M PEG- EPS next Q-0.29 Inst Own87.70% Short Float1.81% Perf Quarter4.39%
Income-27.11M P/S- EPS this Y79.26% Inst Trans26.85% Short Ratio7.55 Perf Half Y26.44%
Sales0.00M P/B3.92 EPS next Y-24.57% ROA-44.07% Short Interest0.45M Perf YTD18.53%
Book/sh3.82 P/C3.79 EPS next 5Y33.18% ROE-48.57% 52W High17.15 -12.71% Perf Year137.62%
Cash/sh3.95 P/FCF- EPS past 3/5Y53.54% - ROIC-27.61% 52W Low6.66 124.88% Perf 3Y3.60%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility2.64% 4.20% Perf 5Y-89.10%
Dividend TTM- EV/Sales- EPS Y/Y TTM83.98% Oper. Margin- ATR (14)1.18 Perf 10Y-99.55%
Dividend Ex-Date- Quick Ratio14.80 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)49.28 Recom1.14
Dividend Gr. 3/5Y- - Current Ratio14.80 EPS Q/Q85.18% SMA20-3.69% Beta0.43 Target Price25.71
Payout- Debt/Eq0.01 Sales Q/Q- SMA503.74% Rel Volume3.71 Prev Close14.57
Employees16 LT Debt/Eq0.01 EarningsMay 14 BMO SMA20025.11% Avg Volume59.04K Price14.97
IPOJun 23, 2014 Option/ShortYes / Yes EPS/Sales Surpr.31.09% - Trades Volume218,867 Change2.75%
Date Action Analyst Rating Change Price Target Change
Dec-16-24Initiated H.C. Wainwright Buy $28
Dec-13-24Initiated Robert W. Baird Outperform $30
Oct-16-24Initiated Oppenheimer Outperform $35
Sep-12-24Initiated Guggenheim Buy $17
Jul-22-24Initiated Leerink Partners Outperform $13
Jun-13-24Initiated Piper Sandler Overweight $30
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Jun-20-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM Loading…
09:40AM
09:40AM
09:40AM
09:40AM
Jun-16-25 08:50AM
Jun-05-25 09:55AM
Jun-04-25 09:40AM
May-29-25 08:50AM
May-20-25 09:55AM
May-19-25 09:40AM
07:00AM Loading…
May-14-25 07:00AM
May-05-25 08:50AM
May-02-25 09:40AM
Apr-30-25 10:17AM
Apr-25-25 09:55AM
Apr-23-25 12:00PM
Apr-16-25 09:40AM
Apr-15-25 11:51PM
Mar-28-25 09:00AM
Mar-25-25 08:00AM
Mar-19-25 07:00AM
Feb-26-25 07:00AM
Feb-20-25 09:55AM
Feb-14-25 08:10AM
08:00AM
08:00AM Loading…
Jan-27-25 08:00AM
Jan-13-25 09:49AM
Dec-17-24 06:25AM
Dec-09-24 09:55AM
08:50AM
Nov-26-24 07:00AM
Nov-14-24 04:30PM
Nov-04-24 08:00AM
Oct-25-24 05:01PM
Oct-14-24 06:00AM
Oct-12-24 06:30AM
Sep-30-24 09:03PM
Sep-26-24 04:30PM
Sep-18-24 08:00AM
Sep-17-24 08:00AM
Jul-15-24 06:00AM
Jul-01-24 07:00AM
May-13-24 02:53PM
08:15AM
May-01-24 08:00AM
Apr-18-24 07:30AM
07:00AM
Apr-09-24 08:00AM
Mar-24-24 07:55AM
Feb-13-24 08:00AM
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
Aug-18-23 09:02PM
Aug-11-23 01:00PM
Aug-08-23 10:30PM
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
08:00AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 03:58PM
Sep-08-21 08:10AM
08:05AM
08:00AM
May-31-21 01:54AM
Apr-27-21 09:55PM
04:44PM
Mar-23-21 12:18PM
07:24AM
07:09AM
Feb-24-21 09:26AM
08:29AM
Dec-07-20 02:33PM
Dec-02-20 12:06AM
Oct-06-20 04:05PM
Oct-02-20 09:05AM
Sep-23-20 04:54PM
Sep-01-20 08:15AM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, LDirectorMar 31 '25Buy12.8316,497211,7368,807,805Apr 02 04:37 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorMar 26 '25Buy13.00900,00011,700,0008,793,245Mar 28 04:51 PM
BUCHI J KEVINDirectorFeb 27 '25Option Exercise3.8651,813199,998103,910Mar 03 02:20 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 23 '24Buy10.9827,502301,9727,981,725Dec 26 04:28 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 24 '24Buy11.2520,018225,2027,999,455Dec 26 04:28 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 03 '24Buy9.6042,000403,2007,957,365Dec 05 04:36 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 20 '24Buy10.2227,436280,3967,920,175Nov 21 04:24 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 19 '24Buy9.7314,000136,2207,895,815Nov 21 04:24 PM